Silmitasertib (CX-4945)

For research use only. Not for use in humans.

目录号：S2248

Silmitasertib (CX-4945) Chemical Structure

CAS No. 1009820-21-6

Silmitasertib (CX-4945)是有效的，选择性CK2(casein kinase 2)抑制剂，无细胞试验中IC50为1 nM,对 Flt3, Pim1 和 CDK1作用效果稍弱(细胞试验中没有活性)。Silmitasertib可诱导自噬并促进细胞凋亡。Phase 1/2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2381.77	现货
1mg	RMB 1040.13	现货
2mg	RMB 1418.29	现货
5mg	RMB 2604.97	现货
50mg	RMB 7289.1	现货
100mg	RMB 10401.33	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Silmitasertib (CX-4945)发表文献88篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Elife, 2021, 10e65962

PubMed: 33890572 ( click the link to review the publication )

Oncogenesis, 2021, 10(3):27

PubMed: 33712563 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(7)3453

PubMed: 33810611 ( click the link to review the publication )

FEBS Open Bio, 2021, 10.1002/2211-5463.13228

PubMed: 34115920 ( click the link to review the publication )

Commun Biol, 2021, 4(1):638

PubMed: 34050247 ( click the link to review the publication )

Cells, 2021, 10(2)338

PubMed: 33562780 ( click the link to review the publication )

bioRxiv, 2021, 10.1101/2021.03.17.435124

PubMed: None ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2289

PubMed: 32385263 ( click the link to review the publication )

Diabetes, 2020, db191186

PubMed: 32540877 ( click the link to review the publication )

Fertil Steril, 2020, 113(5):1067-1079.e5

PubMed: 32386617 ( click the link to review the publication )

Curr Biol, 2020, S0960-9822(20)31413-5

PubMed: 33065005 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(13):E4668

PubMed: 32630015 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

J Anim Sci Biotechnol, 2020, 8;11:31

PubMed: 32292585 ( click the link to review the publication )

Transl Oncol, 2020, 13(1):70-78

PubMed: 31810002 ( click the link to review the publication )

PLoS One, 2020, 15(1):e0227340

PubMed: 31910234 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 27(1):92-104

PubMed: 31925410 ( click the link to review the publication )

Mol Cell, 2019, 74(3):571-583

PubMed: 30898438 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav0318

PubMed: 31803841 ( click the link to review the publication )

EMBO J, 2019, 38(23):e101409

PubMed: 31696965 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(27):13374-13383

PubMed: 31209037 ( click the link to review the publication )
Cell Rep, 2019,

PubMed: 31825822 ( click the link to review the publication )

EBioMedicine, 2019, 49:106-117

PubMed: 31668570 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 18;38(1):131

PubMed: 30885251 ( click the link to review the publication )

Br J Cancer, 2019, 10.1038/s41416-019-0657-5

PubMed: 31776458 ( click the link to review the publication )

Addict Biol, 2019, 10.1111/adb.12808

PubMed: 31364211 ( click the link to review the publication )

Neurobiol Dis, 2019, 126:47-61

PubMed: 29944965 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(4):987-1001

PubMed: 30610108 ( click the link to review the publication )

Cell Cycle, 2019, 18(24):3472-3490

PubMed: 31713447 ( click the link to review the publication )

Oncol Rep, 2019, 10.3892/or.2019.7187

PubMed: 31173270 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:6125068

PubMed: 31531359 ( click the link to review the publication )

Biol Res, 2019, 52(1):22

PubMed: 30992075 ( click the link to review the publication )

Int J Radiat Biol, 2019, 10.1080/09553002.2019.1642531

PubMed: 31290713 ( click the link to review the publication )

Oncol Lett, 2019, 18(4):3845-3856

PubMed: 31579410 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5109-5124

PubMed: 29850896 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):84

PubMed: 30420689 ( click the link to review the publication )

J Biol Chem, 2018, 293(8):2990-3002

PubMed: 29326167 ( click the link to review the publication )

Biomed Pharmacother, 2018, 106:403-410

PubMed: 29966986 ( click the link to review the publication )

Biomed Pharmacother, 2018, 98:357-363

PubMed: 29275177 ( click the link to review the publication )

Biochemistry (Mosc), 2018, 83(11):1380-1387

PubMed: 30482149 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5050-5060

PubMed: 29660033 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

Oncotarget, 2018, 9(18):14597-14607

PubMed: 29581866 ( click the link to review the publication )

Biochemistry (Moscow), 2018, 83-11

PubMed: None ( click the link to review the publication )
Cell Rep, 2017, 18(13):3167-3177

PubMed: 28355568 ( click the link to review the publication )

Exp Mol Med, 2017, 49(9):e375

PubMed: 28883547 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16367

PubMed: 29180680 ( click the link to review the publication )

Cell Signal, 2017, 36:163-175

PubMed: 28487119 ( click the link to review the publication )

J Cell Biochem, 2017, 118(8):2463-2473

PubMed: 28133777 ( click the link to review the publication )

Pancreas, 2017, 46(4):575-581

PubMed: 28196025 ( click the link to review the publication )

PLoS ONE, 2017,

PubMed: 28542269 ( click the link to review the publication )

Heliyon, 2017, 3(6):e00318

PubMed: 28649667 ( click the link to review the publication )

Pharmaceuticals (Basel), 2017, 10(1)E5

PubMed: 28045438 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(36):10145-50

PubMed: 27555590 ( click the link to review the publication )

Cancer Res, 2016, 76(9):2675-86

PubMed: 26980766 ( click the link to review the publication )

J Cell Biol, 2016, 212(3):281-8

PubMed: 26811421 ( click the link to review the publication )

Dis Model Mech, 2016, 9(8):839-48

PubMed: 27483355 ( click the link to review the publication )

Cell Signal, 2016, 28(2):23-31

PubMed: 26577526 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1323-40

PubMed: 26593250 ( click the link to review the publication )

Pharmaceuticals (Basel), 2016, 10(1)E2

PubMed: 28036027 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26793-805

PubMed: 27050366 ( click the link to review the publication )

eNeuro, 2016, 3(6)ENEURO.0092-16.2016

PubMed: 27957526 ( click the link to review the publication )

Tumour Biol, 2016, 37(6):8293-304

PubMed: 26729194 ( click the link to review the publication )

Oncotarget, 2016, 7(52):87361-87372

PubMed: 27888634 ( click the link to review the publication )

Nat Commun, 2015, 6:7227

PubMed: 26085373 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):751-61

PubMed: 25449433 ( click the link to review the publication )

J Mol Cell Cardiol, 2015, 84:191-9

PubMed: 25937534 ( click the link to review the publication )

Biochim Biophys Acta, 2015, 1853(10 Pt A):2207-16

PubMed: 26025678 ( click the link to review the publication )
Int J Biochem Cell Biol, 2015, 61C:81-89

PubMed: 25680545 ( click the link to review the publication )

Mol Cell Biochem, 2015, 404(1-2):103-12

PubMed: 25805179 ( click the link to review the publication )

Anal Biochem, 2015, 468:4-14

PubMed: 25233003 ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1537-42

PubMed: 25750308 ( click the link to review the publication )

Bioconjug Chem, 2015, 26(12):2324-35

PubMed: 26559659 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Nat Immunol, 2015, 16(3):267-75

PubMed: 25599562 ( click the link to review the publication )

Nat Commun, 2014, 5:3393

PubMed: 24569712 ( click the link to review the publication )

Leukemia, 2014, 28(3):543-53

PubMed: 24253024 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1551

PubMed: 25476899 ( click the link to review the publication )

Cell Signal, 2014, 26(12):2809-2817

PubMed: 25194820 ( click the link to review the publication )

Cell Signal, 2014, 26(7):1567-75

PubMed: 24686080 ( click the link to review the publication )

FEBS Lett, 2014, 9(4):e94978

PubMed: 24743259 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

Mol Cell Biochem, 2013, 384(1-2):71-82

PubMed: 23963994 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1830(4):2938-45

PubMed: 23287549 ( click the link to review the publication )

产品安全说明书

Casein Kinase抑制剂选择性比较

生物活性

产品描述

特性

CX-4945是促进人类临床实验的CK2的第一个口服生物相容性小分子抑制剂。

靶点

CK2 ^[1]
(Cell-free assay)

1 nM

体外研究

CX-4945是CK2特异的抑制剂，它只抑制238种激酶中的7种并且在0.5 μM浓度时它的抑制率超过90%，这是CK2的IC50的500多倍。虽然在无细胞系统中CX-4945抑制FLT3, PIM1和CDK1的IC50分别为35 nM, 46 nM和56 nM，但是在细胞基础上的功能实验中10 μM的CX-4945对FLT3, PIM1和 CDK1抑制作用不强。CX-4945有广谱的抗恶性细胞增生活性。乳腺癌细胞系对CX-4945敏感性最广泛，其EC50为1.71-20.01 μM。CX-4945的抗恶性细胞增生活性与CK2α mRNA和蛋白水平对应，但是与CK2α'催化亚基、调整CK2β亚族和PI3K/Akt 或 PTEN突变状态无关。CX-4945通过抑制CK2直接阻断Akt第129位丝氨酸的磷酸化作用来抑制PI3K/Akt信号通路，而不是通过抑制激活的PTEN起作用。用CX-4945处理可以引起磷酸化p21 (T145)减少，而p21和p27整体水平则会升高，同时诱导caspase 3/7活性。用CX-4945处理会诱导BT-474细胞阻断在细胞周期的G2/M期和BxPC-3细胞阻断在G1期。CX-4945会抑制HUVEC的增殖、迁移及血管新生，其IC50分别是5.5 μM, 2 μM和4 μM。在含氧量低的情况下BT-474和BxPC-3细胞用CX-4945处理，能阻断p53和pVHL下调，降低HIF-1α的转录活性^[1]。在Jurkat细胞中CX-4945能有效抑制内源细胞内的内源CK2的活性，其IC50是0.1 μM ^[2]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A431	MVLGeY5kfGmxbjDBd5NigQ>?	NIXDbXMyOCEQvF2=	M33xbFMxKG2rbh?=		NHK3d4ZifHSnboXheIV{KFCLM1utRYt1NW2WT2Kgd4lodmGuaX7n	M2PTSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{i3PVg5Lz5{MkO4O\|k5QDxxYU6=
H2170	NIficppHfW6ldHnvckBCe3OjeR?=	MYOxNEDPxE1?	MoDDN\|AhdWmw		NHLuVmFifHSnboXheIV{KFCLM1utRYt1NW2WT2Kgd4lodmGuaX7n	NVzFenZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzPFc6QDhpPkKyN\|g4QTh6PD;hQi=>
A431	NHPaRlFHfW6ldHnvckBCe3OjeR?=	MX2xNEDPxE1?	NWfPfG1qPC1{NDDo		NH3Sd\|JmdmijbnPld{BieG:ydH;zbZMhf2m2aDDldoxwfGmwaXK=	Ml2wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|OEe5PFgoRjJ{M{i3PVg5RC:jPh?=
H2170	MlXsSpVv[3Srb36gRZN{[Xl?	MofENVAh\|ryP	NF;ZU2Y1NTJ2IHi=		MVPlcohidmOnczDhdI9xfG:\|aYOge4l1cCCncnzveIlvcWJ?	M2PkO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{i3PVg5Lz5{MkO4O\|k5QDxxYU6=
LNCap	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTJOG9COC1\|MDFOwG0>	MYi0JIQ>		MXjJR\|UxRTRwNUpCpO69VQ>?	M1vv[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEOyN\|E3Lz5{MkizNlMyPjxxYU6=
A549	NWTIPXp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PFZ\|AuOzBizszN	NGHZbXI4OiCq	NVznUItFTE2VTx?=	NYLWfHhnUUN3ME20MlE2KM7:TTygbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	NYXKRndrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVE1PDNpPkKzOlUyPDR\|PD;hQi=>
H1299	NWntcHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3n1VFAuOzBizszN	M3nOZ\|czKGh?	NUKwd4E{TE2VTx?=	MoLTTWM2OD1zLkiwJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ3MUS0N{c,OjN4NUG0OFM9N2F-
A549	NIfz[WFHfW6ldHnvckBCe3OjeR?=	MXuxM\|ExKM7:TR?=	M2L2b\|Q5KGh?	MlTRSG1UVw>?	M2jVeIxm[WS\|IITvJIEh\G:\|ZT3k[ZBmdmSnboSg[IVkemWjc3WgbY4hVm:2Y3igdoVxd3K2ZYKgZYN1cX[rdIm=	NFvjfXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[1NVQ1Oyd-MkO2OVE1PDN:L3G+
S-LAMA84	M1vOW2Z2dmO2aX;uJGF{e2G7	NWjYcVJiO8LizszN	NYe2PGcyOjRiaB?=	NYfxOYNuTE2VTx?=	MnjudoVlfWOnczDDT\|Ih[WO2aY\peJk>	MlG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUKxNFkoRjJ2MEGyNVA6RC:jPh?=
R-LAMA84	NWH0RmhCTnWwY4Tpc44hSXO\|YYm=	NH;ZfWc{yqEQvF2=	MVOyOEBp	M2jBRmROW09?	NXXtNYpOemWmdXPld{BEUzJiYXP0bZZqfHl?	M33OO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEGyNVA6Lz5{NECxNlExQTxxYU6=
S-LAMA84	NUDCVHZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWniXXQ5Oi53LUGwJO69VQ>?	MWq0PEBp	M17hXmROW09?	NXvk[VB[cW6qaXLpeJMh[2WubDDndo94fGhiY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpRtgQ>?	MlzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUKxNFkoRjJ2MEGyNVA6RC:jPh?=
R-LAMA84	NXTjN4F4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NES4bGozNjVvMUCg{txO	MnqzOFghcA>?	MmO2SG1UVw>?	NWr6ZZBOcW6qaXLpeJMh[2WubDDndo94fGhiY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpRtgQ>?	MkfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUKxNFkoRjJ2MEGyNVA6RC:jPh?=
A549	MUjGeY5kfGmxbjDBd5NigQ>?	NYXBeVF2OTBizszN	MlTtNVIwOjRxNEigbC=>		MoLibY5pcWKrdIOgWGdHNc7{MT3pcoR2[2WmIH3p[5JifGmxbjDhcoQhcW64YYPpc44>	NH:zbHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECyN\|k{QCd-MkSwNlM6Ozh:L3G+
A549	M{jYS2Z2dmO2aX;uJGF{e2G7	M4HoPFMh\|ryP	MmrnOFghcA>?		MmrMbY5pcWKrdIOgWGdHNc7{MT3pcoR2[2WmIHHjeIl3[XSrb36gc4YhW22jZDDhcoQh\XiycnXzd4lwdiCxZjDTcoFqdCCjbnSgWJdqe3R?	NIHzUWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECyN\|k{QCd-MkSwNlM6Ozh:L3G+
U-266	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjieFcxNTRyIN88US=>	MlzDOFghcA>?		NXjoRWtzUUN3ME2xPU45KML3TdMg	NV3Qc4xqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFY1QTRpPkK0NFg3PDl2PD;hQi=>
INA-6	NHG2XHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HsWlAuPDBizszN	Mk\BOFghcA>?		NGXBXWNKSzVyPUKuOFIhyrWP	NVHT[pFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFY1QTRpPkK0NFg3PDl2PD;hQi=>
Jeko-1	M3S2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HIZVAuPDBizszN	NXHUfYdVPDhiaB?=		M4Ts[GlEPTB;Mj60JOK2VcLi	NE\kZmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4OlQ6PCd-MkSwPFY1QTR:L3G+
Rec-1	NHW2cZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HWfFAuPDBizszN	M3PHcFQ5KGh?		NHXRR2NKSzVyPUGuOFYhyrWPwrC=	M2rG[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi2OFk1Lz5{NEC4OlQ6PDxxYU6=
Jurkat	NFjFcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPUNU0yOCEQvF2=	Mnn2OFghcA>?		MYDJR\|UxRTRwOTFOwG0>	NEDFZ5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK1N\|AzPCd-MkSyOVMxOjR:L3G+
CEM-R	M1TUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVuxMVExKM7:TR?=	MoPIOFghcA>?		MWXJR\|UxRTRizszN	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3M{CyOEc,OjR{NUOwNlQ9N2F-
CEM-S	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfkNU0yOCEQvF2=	M4\wclQ5KGh?		MXHJR\|UxRTRwNjFOwG0>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3M{CyOEc,OjR{NUOwNlQ9N2F-
MOLT-4	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PtZlEuOTBizszN	NILGeGY1QCCq		MnLqTWM2OD13Lkeg{txO	NWjhfGtURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVMxOjRpPkK0NlU{ODJ2PD;hQi=>
PF-382	NH7Edm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVWxMVExKM7:TR?=	M1vTXVQ5KGh?		MmnXTWM2OD12LkWg{txO	NIXuNng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK1N\|AzPCd-MkSyOVMxOjR:L3G+
ALL-SIL	M{fCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfJT483OS1zMDFOwG0>	M2f5W\|Q5KGh?		M176W2lEPTB;NT63JO69VQ>?	MoLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NUOwNlQoRjJ2MkWzNFI1RC:jPh?=
HPB-ALL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljHNU0yOCEQvF2=	M13NdFQ5KGh?		M1;NO2lEPTB;Nj6xJO69VQ>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3M{CyOEc,OjR{NUOwNlQ9N2F-
DND-41	MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33qflEuOTBizszN	NXfOd5JsPDhiaB?=		MXfJR\|UxRTlizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3M{CyOEc,OjR{NUOwNlQ9N2F-
ALL-SIL	MkTERZBweHSxc3nzJGF{e2G7	NFHJXoQ2KM7:TR?=	NHTtSYMzPC92ODDo		NV7C[mhMcW6mdXPld{BieG:ydH;zbZM>	NYfsR5B1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVMxOjRpPkK0NlU{ODJ2PD;hQi=>
DND-41	MlXHRZBweHSxc3nzJGF{e2G7	NYDZS3FpPSEQvF2=	NWWwUYc{OjRxNEigbC=>		Ml3wbY5lfWOnczDhdI9xfG:\|aYO=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3M{CyOEc,OjR{NUOwNlQ9N2F-
MOLT-4	M3XzPGFxd3C2b4Ppd{BCe3OjeR?=	NYfhV3dNPSEQvF2=	NFOwWoczPC92ODDo		MYnpcoR2[2W\|IHHwc5B1d3Orcx?=	NIXjNZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK1N\|AzPCd-MkSyOVMxOjR:L3G+
C2C12	M4rjOmZ2dmO2aX;uJGF{e2G7	M3O0NFMh\|ryP	MlrtNVIwOjRxNEigbC=>		MnS1bY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gc5N1\W:lbHHzeEBlcW[oZYLlcpRq[XSrb36gcYFzc2W{czDhcoQhSWu2IIDoc5NxcG:{eXzheIlwdg>?	M2T4V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkmzNFEyLz5{NEK5N\|AyOTxxYU6=
Nalm6	NGjkdFVHfW6ldHnvckBCe3OjeR?=	NWH1[4pFOTBxMkCg{txO	MofGNlQhcA>?		NXvHUW4zemW\|dXz0d{BqdiCmZXPy[YF{\WRiUGTFUkBxcG:\|cHjvdplt[XSrb36gZZQhfGinIFPLNkB1[XKpZYSgdoV{cWS3ZTDTN\|gxKGGwZDDjc45kd22rdHHueEBld3ewcnXneYxifGmxbjDv[kBRXEWQIIDyc5RmcW5iZYjwdoV{e2mxbh?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4MUe5Nkc,OjR3NkG3PVI9N2F-
SUP-B15	M3TLVGZ2dmO2aX;uJGF{e2G7	MXqxNE8zOCEQvF2=	NFXOSVIzPCCq		MoS2doV{fWy2czDpckBl\WO{ZXHz[YQhWFSHTjDwbI9{eGixconsZZRqd25iYYSgeIhmKEONMjD0ZZJo\XRicnXzbYR2\SCVM{iwJIFv\CClb37jc41qfGGwdDDkc5dvemWpdXzheIlwdiCxZjDQWGVPKHC{b4TlbY4h\XiycnXzd4lwdg>?	NX3TfoMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlE4QTJpPkK0OVYyPzl{PD;hQi=>
Nalm6	MlPXRZBweHSxc3nzJGF{e2G7	MonyOk8yOCEQvF2=	M{nGVFQ5KGh?		MVjpcoR2[2W\|IHHwc5B1d3Orcx?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4MUe5Nkc,OjR3NkG3PVI9N2F-
SUP-B15	M1fi[2Fxd3C2b4Ppd{BCe3OjeR?=	NFzXUXY3NzFyIN88US=>	NYXhOIRDPDhiaB?=		NIP6XXlqdmS3Y3XzJIFxd3C2b4Ppdy=>	NWLrO4ZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlE4QTJpPkK0OVYyPzl{PD;hQi=>
ARPE-19	NVPVZY8yU2mwYYPlJGF{e2G7	MU[1M\|ExNzJyIN88US=>	MUOyOE81QCCq		MkTabY5pcWKrdIOgR2szKGurbnHz[UBi[3Srdnn0fUBifCCjIHPvcoNmdnS{YYTpc44hd2ZiNdMg{txO	NHrpTo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4OlA5OCd-MkS2PFYxQDB:L3G+
ARPE-19	M{TzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUj1Z\|BWOTBizszN	NV7LVI9kOjRvOU[gbC=>	M{H5OWROW09?	Mnv4bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	NEj0Sog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4OlA5OCd-MkS2PFYxQDB:L3G+
HCT116	M{DxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTI[5MyOCEQvF2=	NEDXd3kzPC17NjDo	NWHINYlqTE2VTx?=	MVvpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5	M3T0V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nki2NFgxLz5{NE[4OlA5ODxxYU6=
ARPE-19	NXP5SHRETnWwY4Tpc44hSXO\|YYm=	NIHPSmMyOCEQvF2=	NX60VHB{PCCq	MoG5SG1UVw>?	MXTjZZV{\XNiRWKtd5Rz\XO\|IILld5BwdnOnIH;2[ZIhfGinIICt[WlHOs7zIHLyZY5kcCxiYoX0JIRw\XNibn;0JIlv\HWlZTDDTG9RyqB?	M1;YVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nki2NFgxLz5{NE[4OlA5ODxxYU6=
HCT116	MYXGeY5kfGmxbjDBd5NigQ>?	Mn;TNVAh\|ryP	MV:0JIg>	NXTxbo1JTE2VTx?=	M4r4WoNifXOnczDFVk1{fHKnc4OgdoV{eG:wc3Wgc5ZmeiC2aHWgdE1mUUZ{zsGgZpJidmOqLDDieZQh\G:nczDuc5QhcW6mdXPlJGNJV1EEoB?=	M1;mT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nki2NFgxLz5{NE[4OlA5ODxxYU6=
HCT116	NIXtSodCeG:ydH;zbZMhSXO\|YYm=	NUfzT5FUOTBizszN	NWTTSIdZOjRxNEigbC=>	MX;EUXNQ	Ml3ObY5lfWOnczDhdI9xfG:\|aYO=	MoHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OE[wPFAoRjJ2Nki2NFgxRC:jPh?=
MDA-MB-231	M4TBNGZ2dmO2aX;uJGF{e2G7	MXWyM\|UwOTBizszN	MnjZOEBp		M2n3[oRm[3KnYYPld{B1cGViY3;ud5RqfHW2aY\lJJBpd3OyaH;yfYxifGmxbjDv[kBjd3SqIDDwMXM2OjlvcE[1JIFv\CCyLWOxNlkuSWu2	M17PbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWzO\|I2Lz5{NUG1N\|czPTxxYU6=
MDA-MB-231	NYTZfHFITnWwY4Tpc44hSXO\|YYm=	M4D2R\|IwPS9zMDFOwG0>	NW\4Wld7PCCq		M2DFOIlvcGmkaYTzJJNmemmwZTC1NlkheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWg[ZhxemW\|c3nvckBw\iCLTD22MEBKVC16	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3M{eyOUc,OjVzNUO3NlU9N2F-
U87-MG	MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;ycGJ5OS93L{GwJO69VQ>?	NWixOmVlOjRxNEivO\|IhcA>?	NH[x[ppFVVOR	NGrMbWpqdmirYnn0d{Bk\WyuIHfyc5d1cCCkb4ToJINwdmOnboTyZZRqd25iYX7kJJRqdWViZHXw[Y5l\W62bIm=	MmPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NEG4PVcoRjJ3MkSxPFk4RC:jPh?=
UM-SCC-1	NVfNT4JES2yxbn;n[Y5q[yCDc4PhfS=>	NFLHWVAxNjVvNTFOwG0>	Mlr5NVQh\A>?	M2XQRmROW09?	MUdCpIlvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwh[W6mIIPwbIVz\SCob4LtZZRqd25?	NGHrfok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3PVAyPid-MkWzO\|kxOTZ:L3G+
UM-SCC-46	MX3DcI9vd2enbnnjJGF{e2G7	MVSwMlUuPSEQvF2=	MonXNVQh\A>?	MYXEUXNQ	MWJCpIlvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwh[W6mIIPwbIVz\SCob4LtZZRqd25?	NHLaW3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3PVAyPid-MkWzO\|kxOTZ:L3G+
H28	MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3X5Z\|AvODFvM{Cg{txO	M1Xk[VczKGh?	M4PJS2ROW09?	M2jvSGlEPTB;Nz6yJO69VQ>?	NV7Zd5NzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NlIxQDFpPkK1OFIzODhzPD;hQi=>
H2052	NX:1ZXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{njcVAvODFvM{Cg{txO	MnjCO\|IhcA>?	NVyyPYdOTE2VTx?=	MorNTWM2OD1{LkCg{txO	MoH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MkKwPFEoRjJ3NEKyNFgyRC:jPh?=
PC9/GR	M122PWZ2dmO2aX;uJGF{e2G7	NHfLeGc2KML3TR?=	MmnnOFghcA>?		MlPYbY5lfWOnczDheZRweGijZ4m=	NIDFRW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS4OlQxQSd-MkW0PFY1ODl:L3G+
PC9/ER	NWDqUpoxTnWwY4Tpc44hSXO\|YYm=	NXmzNlZNPSEEtV2=	NWHLbllWPDhiaB?=		NXTtN3BEcW6mdXPld{BifXSxcHjh[5k>	NVXtWIR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PFY1ODlpPkK1OFg3PDB7PD;hQi=>
H1299	NV7jVFY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLuTJM3OS93L{GwJO69VQ>?	MoPIO\|IhcA>?		MkOxbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	NGPuO4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1NFMxQCd-MkW3OVA{ODh:L3G+
Calu-1	NIG3bWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEn2NnEyNzVxMUCg{txO	MVW3NkBp		M1jpfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>	NVjRZVh6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVA{ODhpPkK1O\|UxOzB6PD;hQi=>
H358	MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYWxM\|UwOTBizszN	NVfVdWcyPzJiaB?=		MkHhbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	NIq5VFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1NFMxQCd-MkW3OVA{ODh:L3G+
H1299	MYPBdI9xfG:\|aYOgRZN{[Xl?	MnL1NVAh\|ryP	NXzYcVVHPzJiaB?=		NX61W2dscW6mdXPld{BieG:ydH;zbZM>	NF;3O\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1NFMxQCd-MkW3OVA{ODh:L3G+
Calu-1	MX\BdI9xfG:\|aYOgRZN{[Xl?	NHfwXIwyOCEQvF2=	NHf4TJg4OiCq		M13FNYlv\HWlZYOgZZBweHSxc3nz	NGLkUGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1NFMxQCd-MkW3OVA{ODh:L3G+
H358	NEHkSm9CeG:ydH;zbZMhSXO\|YYm=	MonpNVAh\|ryP	M17ZTlczKGh?		NULVVodNcW6mdXPld{BieG:ydH;zbZM>	M1LBOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{WwN\|A5Lz5{NUe1NFMxQDxxYU6=
NU-DUL	NVH5W4FST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHyw[Zg2NTJ3IN88US=>	MVO0PEBp		NGTEd3lqdmirYnn0d{Bk\WyuIHfyc5d1cCClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6	NUXU[2ZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PFgzPjlpPkK1O\|g5OjZ7PD;hQi=>
Oci Ly 3	MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULmeG57PS1{NTFOwG0>	MYq0PEBp		M4raSolvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>	NEfMdFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PFI3QSd-MkW3PFgzPjl:L3G+
Oci Ly 10	NWHNOpJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfyS3Q2NTJ3IN88US=>	NHSyUYo1QCCq		MnPFbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	MoO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEiyOlkoRjJ3N{i4NlY6RC:jPh?=
Oci Ly 1	M3PLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXSOU0zPSEQvF2=	Ml60OFghcA>?		M1TNfolvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>	NVvmO5dLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PFgzPjlpPkK1O\|g5OjZ7PD;hQi=>
Oci Ly 18	NUm2VpE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljWOU0zPSEQvF2=	MoK4OFghcA>?		MYHpcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	MlXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEiyOlkoRjJ3N{i4NlY6RC:jPh?=
Oci Ly 19	NFjHbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfVWFU2NTJ3IN88US=>	Mn7LOFghcA>?		MXPpcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	MmDWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEiyOlkoRjJ3N{i4NlY6RC:jPh?=
Raji	Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULl[mFWPS1{NTFOwG0>	NHjBPIQ1QCCq		Mo\obY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd6OEK2PUc,OjV5OEiyOlk9N2F-
UM-SCC1	MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoexNE4yNTNyIN88US=>	NWTBPJRsOS13IHS=		Mn[5TWM2OD12LkGg{txO	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7OEC2NUc,OjV5OUiwOlE9N2F-
UM-SCC46	Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmX4NE4yNTNyIN88US=>	NWrVSFRKOS13IHS=		M1vpOGlEPTB;Mz60JO69VQ>?	NGjRVnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5PFA3OSd-MkW3PVgxPjF:L3G+
UM-SCC1	NFPlR3pHfW6ldHnvckBCe3OjeR?=	NH;t[VUxNjVxND:xNEDPxE1?	MWO3NkBp		Ml7F[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiTl[tyNhDNCCEY3ytXGwh[W6mIIXwMZJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBxPTNuIICyNUwhSVBvMTDhcoQhUUxvODDjc45k\W62cnH0bY9vKGSncHXu[IVvfGy7	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7OEC2NUc,OjV5OUiwOlE9N2F-
UM-SCC46	NH30V4RHfW6ldHnvckBCe3OjeR?=	MWqwMlUwPC9zMDFOwG0>	M4P3WFczKGh?		M2roUYRwf25vcnXneYxifGW\|IITo[UBmgHC{ZYPzbY9vKG:oIF7GMeS5SixiQnPsMXhNNCCyNUOsJJAzOSxiQWCtNUBidmRidYCtdoVofWyjdHXzJJRp\SCneIDy[ZN{cW:wIFnMMVgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	NFzDb4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5PFA3OSd-MkW3PVgxPjF:L3G+
HEK293	MYPLbY5ie2ViQYPzZZk>	NIfTU3QxNjYEoN88US=>	NIi1eYIyPSCvaX6=	MYLEUXNQ	NGW4Z\|Nz\WS3Y3XzJGNMOiCtaX7hd4Uh[WO2aY\peJk>	NVvL[HZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFc3OjZpPkK1PFg4PjJ4PD;hQi=>
Hela	MUPLbY5ie2ViQYPzZZk>	NXH6dZRFOC53wrFOwG0>	M2K4TFE2KG2rbh?=	MVXEUXNQ	NFO4Xplz\WS3Y3XzJGNMOiCtaX7hd4Uh[WO2aY\peJk>	M{PVdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEi3OlI3Lz5{NUi4O\|YzPjxxYU6=
LAMA84	NW\BWmh{U2mwYYPlJGF{e2G7	MUOwMlXDqM7:TR?=	NWPSNWM4OTVibXnu	NWTzWGdYTE2VTx?=	MYHy[YR2[2W\|IFPLNkBscW6jc3WgZYN1cX[rdIm=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6N{[yOkc,OjV6OEe2NlY9N2F-
HEK293	NULsXlhkTnWwY4Tpc44hSXO\|YYm=	MnPxN{DPxE1?	NVe2VpRoPSCq	MX\EUXNQ	MVjDT\|IheGixc4Doc5J6dGG2ZYOg[WlHO2piYYSgV4VzOTJ5	NFHETXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4O\|YzPid-MkW4PFc3OjZ:L3G+
HDMEC	NHPkZYpMcW6jc3WgRZN{[Xl?	MXixMVUxKM7:TR?=	MkPtOUBp	NWTNbZN4TE2VTx?=	M{f3eoRm[3KnYYPld{BEUzJia3nuZZNmKGGldHn2bZR6KHerdHjveZQh[W[oZXP0bY5oKGOnbHygeoli[mmuaYT5	NFfhRog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG4PVU5Pid-Mk[xPFk2QDZ:L3G+
HDMEC	M363fmZ2dmO2aX;uJGF{e2G7	NE[1doU2OCEQvF2=	NVzZSpdrOS93IHi=	NH\CT4FFVVOR	NUfaZo1R\GWlcnXhd4V{KHSqZTDueYNt\WG{IIPp[45idCCxZjDwbI9{eGixconsZZRm\CCyNkWgbY4hXE6ILd8xMZN1cW23bHH0[YQhUESPRVRCpC=>	NW\tSIZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xPFk2QDZpPkK2NVg6PTh4PD;hQi=>
A549	NIW4WWhHfW6ldHnvckBCe3OjeR?=	M2XwWFMwOTEEoN88US=>	MoLwOFghcA>?		MkHWd5VxeHKnc4Pld{B1cGVibXnjdo9xcWyuYYKtbY5lfWOnZDDlfJBz\XO\|aX;uJI9nKHBvRlHL	NUDRZ5dmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zNVg5ODBpPkK2N\|E5QDByPD;hQi=>
platelets	MUDLbY5ie2ViQYPzZZk>	MVexM\|UwOTBizszN	NEfHN2QxNjViaB?=	MorpSG1UVw>?	MU\y[YR2[2W\|IFPLNkBscW6jc3WgZYN1cX[rdImgZY5lKHCuYYTlcIV1KGGpZ4Ll[4F1cW:w	NEDsO5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO4NVQ{Pyd-Mk[zPFE1Ozd:L3G+
HDMEC	MUfLbY5ie2ViQYPzZZk>	NILqSmIxNjJ3L{CuOU8yKM7:TR?=	M3roUFI1KGh?	MUXEUXNQ	NGC5eHBz\WS3Y3XzJGNMOiCtaX7hd4Uh[WO2aY\peJktKH[ZRjDlfJBz\XO\|aX;uJIFv\CC\|ZXPy[ZRqd25?	M4LuVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{ixOFM4Lz5{NkO4NVQ{PzxxYU6=
HDMEC	NHfXeohHfW6ldHnvckBCe3OjeR?=	NGTLdZMxNjJ3L{CuOU8yKM7:TR?=	NGf3eGUzPCCq	MoXISG1UVw>?	NUHSVld5emWmdXPld{BmgHC{ZYPzbY9vKG:oIG\DRW0uOSCkdYSgco91KEmFQV2tNS=>	M2TTWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{ixOFM4Lz5{NkO4NVQ{PzxxYU6=
HDMEC	Mn\mSpVv[3Srb36gRZN{[Xl?	MW[xJO69VQ>?	MoPwNlQhcA>?	NFS3OpBFVVOR	NU\KfodZ[W[oZXP0d{B{fWKlZXzseYxieiCub3PhcIl7[XSrb36gc4YhVk[DVHOxJIFv\CCyaH;zdIhwNXB4NR?=	M3fGbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{ixOFM4Lz5{NkO4NVQ{PzxxYU6=
Jurkat	NYfwT\|ZiTnWwY4Tpc44h[XO\|YYm=				NYX0OYt{UW6qaXLpeIlwdiCxZjDDT\|IhcW5iaIXtZY4hUnW{a3H0JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW3fhcY1iOzOSXVHUVEBqdmOxcoDvdoF1cW:wIHnueI8he3Wkc4TyZZRmKGK7IHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNUDPxE1w	M3XQbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUe0OFM1Lz5{MUG3OFQ{PDxxYU6=
MIAPaCa2	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1K4[lQh\GG7cx?=		NF7I[5FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3JRXBiS2F{IHPlcIx{KGGodHXyJFQh\GG7czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFEvOSEQvF2u	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5NESzOEc,OjFzN{S0N\|Q9N2F-
PC3	M{HFRmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWG0JIRigXN?		MnPSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOi5zIN88UU4>	Ml3rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{S0N\|QoRjJzMUe0OFM1RC:jPh?=
HCT116	MkTsRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MlTMOEBl[Xm\|		M2Xie2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IESg[IF6eyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEKuNkDPxE1w	NGW2Xog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3OFQ{PCd-MkGxO\|Q1OzR:L3G+
H1299	NX3BeHFtSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFTkeJY1KGSjeYO=		NFPadXhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFixNlk6KGOnbHzzJIFnfGW{IESg[IF6eyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEKuOEDPxE1w	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5NESzOEc,OjFzN{S0N\|Q9N2F-
Jurkat	NWXlO2NmSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3XQRlQh\GG7cx?=		M2XCS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSoXyb4F1KGOnbHzzJIFnfGW{IESg[IF6eyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEKuOUDPxE1w	NYjKfYpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|Q1OzRpPkKxNVc1PDN2PD;hQi=>
A549	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXq0JIRigXN?		M3jQc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2IHThfZMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSB\|IN88UU4>	NXrnN2l7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|Q1OzRpPkKxNVc1PDN2PD;hQi=>
A375	Mk\4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVHDZ\|B3PCCmYYnz		Mo\PRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDM{e1JINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NEA:KDNwOTFOwG0v	MkK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{S0N\|QoRjJzMUe0OFM1RC:jPh?=
BxPC3	NH3iNHJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1jnS\|Qh\GG7cx?=		MkLhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCEeGDDN{Bk\WyuczDh[pRmeiB2IHThfZMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSB2LkSg{txONg>?	M17BXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUe0OFM1Lz5{MUG3OFQ{PDxxYU6=
LNCAP	M2fiVGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3XqZVQh\GG7cx?=		M{HQfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTF7DRXAh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iND63JO69VS5?	NUPlSXBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|Q1OzRpPkKxNVc1PDN2PD;hQi=>
K562	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1nQUlQh\GG7cx?=		NWnJOIFTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEWuN{DPxE1w	MmS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{S0N\|QoRjJzMUe0OFM1RC:jPh?=
MDA-MB-231	NITrfFdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3vBS\|Qh\GG7cx?=		NH3Lc4tCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hPi52IN88UU4>	NEfRUmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3OFQ{PCd-MkGxO\|Q1OzR:L3G+
MCF7	NYn5WHdtSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MVm0JIRigXN?		M2PiOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2IHThfZMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSB6Lkmg{txONg>?	NFHFWXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3OFQ{PCd-MkGxO\|Q1OzR:L3G+
Hs 578T	NGjO[4hCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYi0JIRigXN?		MkLmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKczC1O\|hVKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEGzMlEh\|ryPLh?=	NWDzdHpNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|Q1OzRpPkKxNVc1PDN2PD;hQi=>
HCT116	M4fySmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYG3NkBpenN?		NIPxc\|lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gOU4zKM7:TT6=	NYPMdnhMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|k1OzNpPkKyN\|M6PDN\|PD;hQi=>
MCF7	M3j0bGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3:yclczKGi{cx?=		NGf6fWVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IE[uOUDPxE1w	NGG0UVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzPVQ{Oyd-MkKzN\|k1OzN:L3G+
A549	NIrMN45CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NETuRZE4OiCqcoO=		NWS1UnJ7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTC4MlIh\|ryPLh?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|OUSzN{c,OjJ\|M{m0N\|M9N2F-
MV4-11	M1TqNWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVixJJRwKDNiZHH5dy=>		MmXTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgZYZ1\XJiMTD0c{A{KGSjeYOgZpkhVVSVIHHzd4F6NCCFQ{WwJF0hOyEQvF2u	MlLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUG4N\|IoRjJ\|N{GxPFMzRC:jPh?=
U937	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlrqNUB1dyB\|IHThfZM>		MnPqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXOUO3JINmdGy\|IHHmeIVzKDFidH:gN{Bl[Xm\|IHL5JG1VWyCjc4PhfUwhS0N3MDC9JFQvOiEQvF2u	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdzMUizNkc,OjN5MUG4N\|I9N2F-
Jurkat	NEnpOFVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MnzNNUB1dyB\|IHThfZM>		NHjJV\|NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFr1dotifCClZXzsd{Bi\nSncjCxJJRwKDNiZHH5d{BjgSCPVGOgZZN{[XluIFPDOVAhRSB2LkWg{txONg>?	NGrJdYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{exNVg{Oid-MkO3NVE5OzJ:L3G+
K562	NYj1TmF4SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Ml63NUB1dyB\|IHThfZM>		MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhOSC2bzCzJIRigXNiYomgUXRUKGG\|c3H5MEBESzVyIE2gO{DPxE1w	MlP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUG4N\|IoRjJ\|N{GxPFMzRC:jPh?=
Sf9	MnLNSpVv[3Srb36gZZN{[Xl?				MXHJcohq[mm2aX;uJI9nKEOGS{KvZ5lkdGmwIFWgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KHW\|aX7nJIhqe3SxbnWgTFEh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKFupYX3tZVM{WF2DVGCsJGlEPTBiPTCxMlgh\|ryPLh?=	M3S2blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkixPVg3Lz5{NE[4NVk5PjxxYU6=
A549	M4LkSmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2XQc\|czKGi{cx?=		MlPMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBESzVyIE2gPU46KM7:TT6=	MoX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6NUCzO\|YoRjJ4OEWwN\|c3RC:jPh?=
Sf21	MmrBSpVv[3Srb36gZZN{[Xl?		NVHte3lWQTBibXnudy=>		MonYTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDOMZRmem2rbnHsJGhqezZvdHHn[4VlKEONMnHsdIhiKGW6cILld5Nm\CCrbjDT[lIyKGmwc3XjeEBk\WyuczD1d4lv\yCFS{L0bYRmKGG\|IIP1ZpN1emG2ZTD0doVifGWmIH\vdkAzOCCvaX7zJI1m[XO3cnXkJIFnfGW{IEmwJI1qdnNiaX6gdJJme2WwY3Wgc4YhVWeFbEKgZpkh[2GuaYDldkBud2KrbHn0fUB{cGmodDDhd5NigSxiSVO1NEA:KDBwMECzJO69VS5?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV3OUK3PEc,Ojl3NUmyO\|g9N2F-
Vero E6	M4HwVGFvfGm4aYLhcEBie3OjeR?=		MoHaOFghcA>?		NFPJXW9KSzVyIH\vdkBidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBUSVKVLVPvWk0zKGmwIITo[UBX\XKxIFW2JINmdGxibHnu[UBifCB2ODDoJIJ6KGmvbYXuc4ZtfW:{ZYPj[Y5k\S2kYYPl[EBie3OjeTCo[IV1\WO2aX7nJJRp\SC4aYLhcEBPWCCycn;0[YlvKGmwIITo[UBvfWOuZYXzJI9nKHSqZTDW[ZJwKEV4IHPlcIx{MS5uIFnDOVAhRSB\|Lki5NFQ2KM7:TT6=	NFjBfWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MkO1N\|g2QSd-M{KzOVM5PTl:L3G+
A549	NILGZVBHfW6ldHnvckBie3OjeR?=	NUnnfpBbOzBidV2=	MWG0PEBpenN?		NVvvVWlGUW6qaXLpeIlwdiCxZjDDT\|IudWWmaXH0[YQhVU2SMjDhZ5RqfmG2aX;uJIlvKGi3bXHuJGE2PDliY3XscJMh[XRiM{CgeW0h[W[2ZYKgOFghcHK\|IHL5JIdmdGG2aX6tfplud2e{YYDofS=>	M1PV[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEGyNVI1Lz5{NECxNlEzPDxxYU6=
A549	M3zRU2Z2dmO2aX;uJIF{e2G7	NUTuW5VMOTBidV2=	M3rJUFE2KHSxIEOwJI1qdnN?		M4HIO2lvcGmkaYTpc44hd2ZiQ1uyMY1m\GmjdHXkJGVTUyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hSTV2OTDj[YxteyCjdDCxNEB2VSCjZoTldkAyPSC2bzCzNEBucW6\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	M3rDRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEGyNVI1Lz5{NECxNlEzPDxxYU6=
A549	NGSzSIJHfW6ldHnvckBie3OjeR?=	MVSxJJRwKDFyIIXN	NIrkVYUzPCCqcoO=		NYXjeo17UW6qaXLpeIlwdiCxZjDDT\|IudWWmaXH0[YQhVVRzLV3NVEBmgHC{ZYPzbY9vKGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYSgNUB1dyBzMDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=>	M4HwUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEGyNVI1Lz5{NECxNlEzPDxxYU6=
A549	MVfGeY5kfGmxbjDhd5NigQ>?	MV:xNEB2VQ>?			NFnW[Y5KdmirYnn0bY9vKG:oIFPLNk1u\WSrYYTl[EBGWkticHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYSgNVAhfU1iYomgW4V{fGW{bjDicI91KG2ndHjv[C=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzMkGyOEc,OjRyMUKxNlQ9N2F-
A549	MWfGeY5kfGmxbjDhd5NigQ>?	M4O3OlExKHWP	NWX5V3E1OjRiaILz		NFjOfVlKdmirYnn0bY9vKG:oIFPLNk1u\WSrYYTl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R?	Mn;DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUKxNlQoRjJ2MEGyNVI1RC:jPh?=
A549	NXTlbmlJTnWwY4Tpc44h[XO\|YYm=	M1nyOVExKHWP	MnG5OEB1dyB{NDDodpM>		NGP1OHZKdmirYnn0bY9vKG:oIFPLNk1u\WSrYYTl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhPCC2bzCyOEBpenNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=>	MlvjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUKxNlQoRjJ2MEGyNVI1RC:jPh?=
U-2 OS	NWCxV49IeUiWUzDhd5NigQ>?				MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	NHexS\|FyUFSVIHHzd4F6				M4jDepFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	Mk\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NYKybpNDeUiWUzDhd5NigQ>?				NV3BXI9VeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	M3fQ[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	MV3xTHRUKGG\|c3H5				Ml\PdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	M2HVTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	NIX5dlRyUFSVIHHzd4F6				MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	M2H2ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	M2i4ZpFJXFNiYYPzZZk>				MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	NXnENJBmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NEL4VIdyUFSVIHHzd4F6				M1PMPZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	MYnxTHRUKGG\|c3H5				MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NYq5XZNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NYjZPHJNeUiWUzDhd5NigQ>?				MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	NULVU25LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NEnpWlRyUFSVIHHzd4F6				NH;1OWhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	M2rlOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	MnPxdWhVWyCjc4PhfS=>				NEXzdGZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	NInzOZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MkHadWhVWyCjc4PhfS=>				NXy0PGlLeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	MVvxTHRUKGG\|c3H5				NF\2R45yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	MmDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NWrzN2RHeUiWUzDhd5NigQ>?				NIS5W4tyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	M4m3d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	MonJdWhVWyCjc4PhfS=>				NUfF[lJGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	NXuweFZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	MXHxTHRUKGG\|c3H5				NILlOolyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	MWfxTHRUKGG\|c3H5				NFzRfJFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	M4rUSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-S6K1(T389) / S6K1 / p-S6(S235/236) / S6; PubMed: 30683840 Cell Death Dis DLD-1 cells were incubated with 25 μM silmitasertib for 16 h. The levels of the indicated proteins were analyzed by western blot. p-AKT(S129) / p-AKT(T308) / p-AKT(S473) / AKT / p-ERK / ERK / TP53 / p-p21(Th145) / p21 / Bcl-xl; PubMed: 25798061 Int J Biol Sci CX-4945 altered PI3K/AKT/Bcl-XL, ERK/AP-1 and TP53/p21proteins in HNSCC. UM-SCC-1 (left) and UM-SCC-46 (right) cell lines were treated with 4 and 10 μM CX-4945, whole cell lysates were harvested 6 and 24 hours after treatment, and subjected to SDS-PAGE and Western blot of indicated proteins. β-action was used as a loading control. p-Smad2 (Cytosol) / Smad2/3 (Cytosol) / Smad2/3 (Nucleus) / Twist / Snail; PubMed: 24023938 PLoS One The effect of CX-4945 on TGF-β1-induced activation of Smad and expression of Snail and Twist was evaluated using Western blot analysis. Briefly, after 24 h serum starvation, A549 cells were treated with TGF-β1 (5 ng/ml) alone or in combination with CX-4945 in media containing 0.1% FBS for 48 h. Cytosolic and Nuclear fractions were obtained. Actin and histone H3 were used as internal control of cytosolic and nuclear fraction, respectively. The relative, normalized ratio between p-Smad2 and actin was presented.	30683840 25798061 24023938
Immunofluorescence	β-catenin; PubMed: 24023938 PLoS One Nuclear translocation of β-catenin and its inhibition by CX-4945 were confirmed by immunocytochemistry. Nuclei were counterstained with Hoechst 33342. All scale bars represent 20 µm. E-cadherin / Vimentin; PubMed: 24023938 PLoS One The effect of CX-4945 on the TGF-β1-induced expression of epithelial and mesenchymal markers was evaluated by immunocytochemistry. Briefly, after 24 h serum starvation, A549 cells were treated with TGF-β1 (5 ng/ml) alone or in combination with CX-4945 in media containing 0.1% FBS for 72 h. All scale bars represent 200 µm.	24023938
Growth inhibition assay	Cell viability; PubMed: 30316146 Transl Oncol CX-4945 decreases cell viability of HuCCT1, EGI-1, and Liv27 CCA cell lines in dose-dependent manner (IC50of 7.3, 9.5, and 9.4 μM, respectively) (A)	30316146

体内研究

在BT-474模型中，一天两次口服25 mg/kg或75 mg/kg的CX-4945，具有强效的抗癌活性，TGI分别为88% 和97%，每组实验动物9只中有2只其肿瘤的体积大小比初期的要减少50%。在BxPC-3模型中，一天两次用75 mg/kg的CX-4945处理，TGI为93%，在治疗期结束时，有3只动物没发现还有残留的肿瘤^[1]。在PC3异种移植的模型中，用25 mg/kg, 50 mg/kg或 75 mg/kg的CX-4945处理，能抑制肿瘤生长，TGI分别为19%, 40%和86%^[2]

激酶实验：^[2]	- 合并 CK2激酶实验: 将10 μL稀释缓冲液(ADB; 20 mM MOPS, pH 7.2, 25 mM β-磷酸甘油, 5 mM EGTA, 1 mM原钒酸钠和 1 mM 二硫苏糖醇)，10 μL多肽底物(RRRDDDSDDD, 溶于ADB，浓度1mM)和10 μL重组的人源CK2(ααββ-全酶, 25 ng溶于ADB)混合，加入10 μL CX-4945。加入10μLATP溶液(90% 75 mM MgCl ₂, 75 μM ATP (终浓度15 μM)溶于ADB; 10% [γ-³³P]ATP (储存1 mCi/100 μL; 3000 Ci/mM起始反应，30 ℃反应10分钟。用100 μL的0.75%的磷酸终止反应，然后转移到磷酸纤维素滤板上过滤。每个孔用0.75%磷酸洗5次，真空抽干5分钟，再每孔加入15 μL闪烁液，然后用Wallac荧光计数器检测残留的放射性。通过对0.0001 μM 到1 μM的8个浓度的CX-4945实验结果的检测，计算出IC50。
细胞实验：^[1]	- 合并 Cell lines: SKBr3, MDA-MB-453, BT-474, ZR-75-1, MDA-MB-231, MDA-MB-468, T47D, MCF 7, Hs578T, MDA-MB-361, UACC-812, 等等 Concentrations: 溶于 DMSO, 终浓度 ~100 μM Incubation Time: 4 天 Method: 在用药处理前，在合适的培养基中按每孔3000个细胞的浓度接种细胞培养24小时，然后用不同浓度的CX-4945处理细胞。接种悬浮细胞并处理相同的天数。接着孵育4天，加入Alamar Blue (20 μL, 体积比每孔10%)，然后于37℃孵育4-5小时。检测荧光，激发光为530-560 nm，放射光为590 nm。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 注射了BxPC-3 或BT-474细胞的免疫缺陷的雌鼠 Dosages: 25或75 mg/kg Administration: 每日两次口服 (Only for Reference)

参考文献

[4] Bliesath J, et al. Cancer Lett, 2012, 322(1), 113-118.

- 合并

溶解度 (25°C)

体外	DMSO	16 mg/mL (45.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% CMC Na	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Silmitasertib (CX-4945) SDF

分子量	349.77
化学式	C₁₉H₁₂ClN₃O₂
CAS号	1009820-21-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04668209	Recruiting	Drug: Silmitasertib	Coronavirus	University of Arizona\|Senhwa Biosciences Inc.	January 1 2021	Phase 2
NCT04663737	Recruiting	Drug: Silmitasertib\|Drug: SOC	Covid19	Chris Recknor MD\|Senhwa Biosciences Inc.	December 3 2020	Phase 2
NCT03904862	Recruiting	Drug: CX 4945	Medulloblastoma Childhood	Pediatric Brain Tumor Consortium\|St. Jude Children''s Research Hospital\|National Cancer Institute (NCI)	March 18 2019	Phase 1\|Phase 2
NCT02128282	Active not recruiting	Drug: CX-4945\|Drug: Cisplatin\|Drug: Gemcitabine	Cholangiocarcinoma	Senhwa Biosciences Inc.	June 2014	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to reconstitute the compound (S2248) for in vivo uses?
回答：
For injection, CX-4945 can be dissolved in 2% DMSO+30% PEG 300+2% Tween 80+ddH2O at 5mg/ml clearly. When making the solution, please dissolve the compound in DMSO clearly first. If it dissolves not readily, please sonicate and warm the solution in water bath at about 45-50℃. Then add PEG and Tween. After they mixed well, dilute with water. For oral gavage, CX-4945 can be dissolved in 1% CMC Na at 30mg/ml as a homogeneous suspension. This is a common formulation for oral gavage, and is convenience to prepare.

研究领域

产品类型

定制您的化合物库

Silmitasertib (CX-4945)

客户使用Selleck生产的Silmitasertib (CX-4945)发表文献88篇：

产品安全说明书

Casein Kinase抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Silmitasertib (CX-4945) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

常见问题及建议解决方法